Oncotarget

Reviews:

Mesenchymal stem cells in idiopathic pulmonary fibrosis

Xiaohong Li, Shaojie Yue and Ziqiang Luo _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:102600-102616. https://doi.org/10.18632/oncotarget.18126

Metrics: PDF 2141 views  |   HTML 3140 views  |   ?  


Abstract

Xiaohong Li1, Shaojie Yue2 and Ziqiang Luo1

1 Department of Physiology, Xiangya School of Medicine, Central South University, Changsha, China

2 Department of Neonatology, Xiangya Hospital, Central South University, Changsha, China

Correspondence to:

Ziqiang Luo, email:

Keywords: idiopathic pulmonary fibrosis, mesenchymal stem cells, mobilization, secretome, immunomodulation

Received: March 03, 2017 Accepted: May 07, 2017 Published: May 23, 2017

Abstract

Idiopathic pulmonary fibrosis (IPF) is a major cause of respiratory failure in critically ill patients and common outcome of various lung interstitial diseases. Its mortality remains high, and no effective pharmacotherapy, in addition to artificial ventilation and transplantation, exists. As such, the administration of mesenchymal stem or stromal cells (MSCs) is currently investigated as a new therapeutic method for pulmonary fibrosis. Clinical trials on MSC-based therapy as a potential treatment for lung injury and fibrosis are also performed. MSCs can migrate to injured sites and secrete multiple paracrine factors and then regulate endothelial and epithelial permeability, decrease inflammation, enhance tissue repair, and inhibit bacterial growth. In this review, recent studies on stem cells, particularly MSCs, involved in alleviating lung inflammation and fibrosis and their potential MSC-induced mechanisms, including migration and differentiation, soluble factor and extracellular vesicle secretion, and endogenous regulatory functions, were summarized.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18126